More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$42.45B
EPS
8.21
P/E ratio
32.2
Price to sales
2.52
Dividend yield
--
Beta
1.164282
Previous close
$264.73
Today's open
$263.79
Day's range
$257.36 - $264.08
52 week range
$154.50 - $284.50
show more
CEO
Ari Bousbib
Employees
94000
Headquarters
Durham, NC
Exchange
New York Stock Exchange
Shares outstanding
164800000
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know
IQV's growth is fueled by rising clinical research demand, strong commercial services momentum, AI adoption and operational efficiencies that boost profitability.
Zacks Investment Research • Nov 13, 2026

Artisan Select Equity Fund Q3 2026 Portfolio Review
Meta shares rose 29% after the company launched a new AI product called Muse, which is designed to make agentic AI capabilities accessible to ordinary consumers. IQVIA shares were up 39% as industry demand trends improved in drug development and the notion that the company was AI roadkill lost a bit of steam. Universal Music Group shares declined 22% due to a disappointing earnings report.
Seeking Alpha • Nov 12, 2026

IQVIA: 3 Key Takeaways for Long-Term Investors
Net new clinical bookings reached $3.2 billion in the third quarter. Last 12-month net new bookings increased 14% to $11.7 billion.
The Motley Fool • Nov 10, 2026

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Oct 29, 2026

Artisan Global Value Fund Q3 2026 Portfolio Discussion
US government debt-to-GDP exceeds 120%, while annual interest payments now surpass the budget for national defense. Our three best-performing stocks this quarter were Meta, IQVIA and Shell. Our three largest detractors this quarter were Danone, Heidelberg and Samsung Electronics.
Seeking Alpha • Oct 29, 2026

What IQVIA (IQV) Said on Its Q3 Earnings Call
IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.
MarketBeat • Oct 27, 2026

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript
IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 27, 2026

IQVIA Reports Third-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2026. Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance eff.
Business Wire • Oct 27, 2026

IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.
Zacks Investment Research • Oct 27, 2026

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.
Zacks Investment Research • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell IQVIA Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.